Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

Published:2018-03-13 Issue:10 Volume:124 Page:2174-2183
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Goss Glenwood D.¹^ORCID,Vokes Everett E.²,Gordon Michael S.³,Gandhi Leena⁴,Papadopoulos Kyriakos P.⁵,Rasco Drew W.⁵,Fischer JuDee S.⁶,Chu Katharine L.⁶,Ames William W.⁶,Mittapalli Rajendar K.⁶,Lee Ho-Jin⁶,Zeng Jiewei⁶,Roberts-Rapp Lisa A.⁶,Loberg Lise I.⁶,Ansell Peter J.⁶,Reilly Edward B.⁶,Ocampo Christopher J.⁶,Holen Kyle D.⁶,Tolcher Anthony W.⁵

Affiliation:

1. The Ottawa Hospital Research Institute and the University of Ottawa; Ottawa Ontario Canada

2. Department of Medicine; University of Chicago; Chicago Illinois

3. HonorHealth Research Institute; Scottsdale Arizona

4. New York University Perlmutter Cancer Center; NYU Health; New York New York

5. South Texas Accelerated Research Therapeutics; San Antonio Texas

6. AbbVie, Inc; North Chicago Illinois

Funder

AbbVie

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

1. Epidermal growth factor receptor (EGFR) signaling in cancer;Normanno;Gene.,2006

2. Cetuximab for the treatment of colorectal cancer;Jonker;N Engl J Med.,2007

3. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival;Bonner;Lancet Oncol.,2010

4. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations [serial online];Liang;PLoS One.,2014

5. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody;Reilly;Mol Cancer Ther.,2015

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Intracellular and Extracellular Vesicles in the Development of Therapy Resistance in Cancer;Current Pharmaceutical Design;2024-10

2. Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report;Blood Cancer Journal;2024-08-07

3. A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies;Cancer Treatment Reviews;2024-07

4. Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies;British Journal of Clinical Pharmacology;2024-06-23

5. Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer;Carcinogenesis;2024-02-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3